Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCamidge, D. Ross
dc.contributor.authorAhn, Myung-Ju
dc.contributor.authorYang, James C. H.
dc.contributor.authorHan, Ji-Youn
dc.contributor.authorHochmair, Maximilian J.
dc.contributor.authorFelip Font, Enriqueta
dc.contributor.authorKim, Hye Ryun
dc.date.accessioned2021-09-23T11:08:10Z
dc.date.available2021-09-23T11:08:10Z
dc.date.issued2020-11-01
dc.identifier.citationCamidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 1;38(31):3592–603.
dc.identifier.issn1527-7755
dc.identifier.urihttps://hdl.handle.net/11351/6346
dc.descriptionCàncer de pulmó; Brigatinib; Estudi ALTA-1L
dc.description.sponsorshipSupported by ARIAD Pharmaceuticals, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Professional medical writing assistance was provided by Lauren Gallagher, RPh, PhD, and Lela Creutz, PhD, of Peloton Advantage, Parsippany, NJ, an OPEN Health company, and funded by Millennium Pharmaceuticals. Supported by National Health Service funding to the Royal Marsden Hospital/Institute of Cancer Research NIHR Biomedical Research Centre (S.P.).
dc.language.isoeng
dc.publisherAmerican Society of Clinical Oncology
dc.relation.ispartofseriesJournal of Clinical Oncology;38(31)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPulmons - Càncer - Tractament
dc.subjectMedicaments antineoplàstics - Ús terapèutic - Eficàcia
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshProgression-Free Survival
dc.titleBrigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1200/JCO.20.00505
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decssupervivencia libre de progresión
dc.relation.publishversionhttps://doi.org/10.1200/JCO.20.00505
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Camidge DR] University of Colorado Cancer Center, Aurora, CO. [Kim HR] Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. [Ahn MJ] Samsung Medical Center, Seoul, South Korea. [Yang JCH] National Taiwan University Hospital, Taipei, Taiwan. [Han JY] National Cancer Center, Goyang, South Korea. [Hochmair MJ] Department of Respiratory and Critical Care Medicine, Krankenhaus Nord–Klinik Floridsdorf, Vienna, Austria. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid32780660
dc.identifier.wos000588411100004
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple